These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31909480)

  • 21. [Agranulocytosis induced by dapsone prescribed for dermatitis herpetiformis].
    Machet L; Callens A; Mercier E; Gargot S; Lorette G; Vaillant L
    Ann Dermatol Venereol; 1996; 123(5):328-30. PubMed ID: 8761086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic insight into the activity of a sulfone compound dapsone on Propionibacterium (Newly Reclassified as Cutibacterium) Acnes-mediated cytokine production.
    Geyfman M; Debabov D; Poloso N; Alvandi N
    Exp Dermatol; 2019 Feb; 28(2):190-197. PubMed ID: 30585659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits?
    Temiz SA; Daye M
    Cutan Ocul Toxicol; 2022 Mar; 41(1):60-66. PubMed ID: 34969324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction.
    Debol SM; Herron MJ; Nelson RD
    J Leukoc Biol; 1997 Dec; 62(6):827-36. PubMed ID: 9400824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newer topical therapies for the treatment of acne vulgaris.
    Del Rosso JQ
    Cutis; 2007 Nov; 80(5):400-10. PubMed ID: 18189027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring.
    Gkalpakiotis S; Arenberger P; Sticova E; Sefrnova P; Arenbergerova M
    J Dermatol; 2012 Dec; 39(12):1074-5. PubMed ID: 22784106
    [No Abstract]   [Full Text] [Related]  

  • 27. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
    Stotland M; Shalita AR; Kissling RF
    Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An unusual clinical presentation of pemphigus herpetiformis with marked response to dapsone.
    Montgomery JR; Chan LS
    J Am Acad Dermatol; 2011 Aug; 65(2):436-438. PubMed ID: 21763574
    [No Abstract]   [Full Text] [Related]  

  • 29. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
    Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
    J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic use of dapsone in dermatitis herpetiformis (Duhring) and in certain inflammatory skin diseases].
    Révész K; Schneider I
    Orv Hetil; 1995 Jan; 136(2):59-62. PubMed ID: 7862431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapsone 5% gel: a new option in topical therapy for acne.
    Tan J
    Skin Therapy Lett; 2012 Sep; 17(8):1-3. PubMed ID: 22949131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?
    Anzengruber F; Schenk J; Graf V; Nordmann TM; Guenova E; Dummer R
    Dermatology; 2020; 236(3):183-190. PubMed ID: 31509850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis.
    Stendahl O; Molin L; Dahlgren C
    J Clin Invest; 1978 Jul; 62(1):214-20. PubMed ID: 207742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral acantholytic itching disease responding to dapsone. Dermatitis herpetiformis, pemphigus, or a new disease?
    Lindgren S; Enerbäck L; Freiberg N
    Oral Surg Oral Med Oral Pathol; 1976 Nov; 42(5):597-605. PubMed ID: 1068417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypersensitivity reaction to dapsone: report from Malaysia.
    Mohamed KN
    Lepr Rev; 1984 Dec; 55(4):385-9. PubMed ID: 6527602
    [No Abstract]   [Full Text] [Related]  

  • 36. Acne fulminans successfully treated with prednisone and dapsone.
    Lages RB; Bona SH; Silva FV; Gomes AK; Campelo V
    An Bras Dermatol; 2012; 87(4):612-4. PubMed ID: 22892777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable.
    Tanghetti E; Harper JC; Oefelein MG
    J Drugs Dermatol; 2012 Dec; 11(12):1417-21. PubMed ID: 23377510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
    Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
    J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
    Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
    J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-Daily Topical Dapsone Gel, 7.5%: Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females.
    Tanghetti E; Harper J; Baldwin H; Kircik L; Bai Z; Alvandi N
    J Drugs Dermatol; 2018 Nov; 17(11):1192-1198. PubMed ID: 30500139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.